No Data
No Data
No Data
No Data
No Data
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
BASEL, Switzerland and LONDON and NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday,
GlobeNewswireJan 30 16:05 ET
Roche Completes Acquisition of Telavant From Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OT
GlobeNewswireDec 14, 2023 09:00 ET
Roivant and Priovant Announce Results From Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52Priovant plans to continue progressing the program in indications ou
GlobeNewswireNov 27, 2023 08:00 ET
Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective im
GlobeNewswireNov 10, 2023 08:00 ET
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 202
GlobeNewswireOct 30, 2023 17:30 ET
Roivant Announces Completion of Redemption of Its Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it completed the redemption of its outstanding public warrants (the "Public Warrants") and
GlobeNewswireSep 11, 2023 08:00 ET
No Data
No Data